Metabolomic profiling of exhaled breath condensate identifies a novel biomarker panel for detecting thyroid and breast cancer

BACKGROUND: The non-invasive detection of cancer via exhaled breath condensate (EBC) represents a promising frontier in oncology. This study explores the metabolic profiles of EBC to identify biomarkers for the early detection of thyroid cancer (TC) and breast cancer (BC), and to investigate potential metabolic interrelationships between them. METHODS: We conducted gas chromatography-mass spectrometry (GC-MS) analysis of EBC samples from 74 individuals, including 65 cancer patients (TC and BC) and 9 non-cancer controls. Comparative statistical analyses and machine learning were employed to identify discriminant metabolites. RESULTS: 305 metabolites were identified in total. Comparative analysis revealed 16 differential metabolites in cancer patients versus controls, with 14 specific to TC and 7 to BC. Notably, five metabolites were common to both cancers: 1,2-Bis(trimethylsilyl)benzene, 1,4-Phthalazinedione,2,3-dihydro-6-nitro-, Eicosane, Methyltris (trimethylsiloxy) silane, and Octadecane, highlighting metabolites that were commonly altered in both cancer types. ROC analysis demonstrated strong diagnostic potential: 1,2-Bis(trimethylsilyl)benzene effectively discriminated cancer from controls (AUC = 0.822) and identified TC (AUC = 0.866), while 1,4-Phthalazinedione,2,3-dihydro-6-nitro- detected BC (AUC = 0.783). Combinations of metabolites yielded AUCs > 0.7 for both cancers. However, limited discriminatory power was observed between TC and BC (maximum AUC = 0.663), indicating significant metabolic similarity. Furthermore, specific metabolite abundances correlated with conventional serum biomarkers, thyroid hormone levels, and lymphatic metastasis. CONCLUSION: Our findings establish EBC metabolomics as a powerful, non-invasive tool for early cancer detection and monitoring. The identification of shared metabolic alterations between TC and BC suggests common metabolic features that warrant further investigation and paves the way for developing breath-based diagnostic assays.

Authors

Institutions

Publication Details

Journal
Discover Oncology
Published
2026-05-18
DOI
https://doi.org/10.1007/s12672-026-05150-6
Primary Topic
Advanced Chemical Sensor Technologies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Metabolomic profiling of exhaled breath condensate identifies a novel biomarker panel for detecting thyroid and breast cancer

Yawen Yu, Ping Yang, Guoqiang Bao, Lijuan Yuan et al.
Discover Oncology
Advanced Chemical Sensor Technologies
article

Metabolomic profiling of exhaled breath condensate identifies a novel biomarker panel for detecting thyroid and breast cancer

Yawen Yu, Ping Yang, Guoqiang Bao, Lijuan Yuan, Fangning Gao, Shujia Peng, Mao Sun
article en

Abstract

BACKGROUND: The non-invasive detection of cancer via exhaled breath condensate (EBC) represents a promising frontier in oncology. This study explores the metabolic profiles of EBC to identify biomarkers for the early detection of thyroid cancer (TC) and breast cancer (BC), and to investigate potential metabolic interrelationships between them. METHODS: We conducted gas chromatography-mass spectrometry (GC-MS) analysis of EBC samples from 74 individuals, including 65 cancer patients (TC and BC) and 9 non-cancer controls. Comparative statistical analyses and machine learning were employed to identify discriminant metabolites. RESULTS: 305 metabolites were identified in total. Comparative analysis revealed 16 differential metabolites in cancer patients versus controls, with 14 specific to TC and 7 to BC. Notably, five metabolites were common to both cancers: 1,2-Bis(trimethylsilyl)benzene, 1,4-Phthalazinedione,2,3-dihydro-6-nitro-, Eicosane, Methyltris (trimethylsiloxy) silane, and Octadecane, highlighting metabolites that were commonly altered in both cancer types. ROC analysis demonstrated strong diagnostic potential: 1,2-Bis(trimethylsilyl)benzene effectively discriminated cancer from controls (AUC = 0.822) and identified TC (AUC = 0.866), while 1,4-Phthalazinedione,2,3-dihydro-6-nitro- detected BC (AUC = 0.783). Combinations of metabolites yielded AUCs > 0.7 for both cancers. However, limited discriminatory power was observed between TC and BC (maximum AUC = 0.663), indicating significant metabolic similarity. Furthermore, specific metabolite abundances correlated with conventional serum biomarkers, thyroid hormone levels, and lymphatic metastasis. CONCLUSION: Our findings establish EBC metabolomics as a powerful, non-invasive tool for early cancer detection and monitoring. The identification of shared metabolic alterations between TC and BC suggests common metabolic features that warrant further investigation and paves the way for developing breath-based diagnostic assays.

Discover Oncology
Ningbo College of Health Sciences (CN), Tang Du Hospital (CN), Air Force Medical University (CN)
Openalex Percentile: Top 10%
Advanced Chemical Sensor Technologies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.